Petros Pharmaceuticals (PTPI) News Today → Next President (Not Trump. Not Biden.) (From The Freeport Society) (Ad) Free PTPI Stock Alerts $0.61 +0.03 (+4.92%) (As of 05/31/2024 08:51 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 29, 2024 | finance.yahoo.comPetros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) (avanafil) OTC SwitchMay 21, 2024 | finance.yahoo.comPetros Pharmaceuticals Activates Advisory Committee to Help Guide Rx-to-OTC Switch for STENDRAMay 16, 2024 | investorplace.comPTPI Stock Earnings: Petros Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024April 25, 2024 | finance.yahoo.comPetros Pharmaceuticals announces online distribution for lead ED product with Lemonaid HealthApril 23, 2024 | finanznachrichten.dePetros Pharmaceuticals, Inc.: Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA Through New Agreement with Lemonaid HealthApril 18, 2024 | markets.businessinsider.comPositive Outlook for Petros Pharmaceuticals: Buy Rating Affirmed Amidst FDA Advances and Promising Stendra DevelopmentsApril 2, 2024 | markets.businessinsider.comPetros Pharma Stock Down, Despite Positive Results For Stendra StudyApril 2, 2024 | investorplace.comPTPI Stock Earnings: Petros Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023March 20, 2024 | finanznachrichten.dePetros Pharmaceuticals, Inc.: Petros Pharmaceuticals Successfully Launches AI Tool In Collaboration with Multi-Billion-Dollar Software ProviderMarch 6, 2024 | morningstar.comPetros Pharmaceuticals Inc Ordinary Shares PTPIFebruary 14, 2024 | finance.yahoo.comPetros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software ProviderFebruary 14, 2024 | marketbeat.comTrading was temporarily halted for "PTPI" at 09:02 AM with a stated reason of "LULD pause."January 30, 2024 | uk.investing.comPetros Pharmaceuticals Inc (PTPI)January 24, 2024 | finance.yahoo.comPetros Pharmaceuticals Announces Two Upcoming FDA Meetings to Review Progress and Path Forward for STENDRA(R) (avanafil) Rx-to-OTC SwitchJanuary 17, 2024 | finance.yahoo.comPetros Pharmaceuticals Demonstrates Positive Results Following Successful Completion of Initial Cohort of Phase 2 Equivalent Self-Selection Study for STENDRA (avanafil) Rx-to-OTC SwitchDecember 14, 2023 | markets.businessinsider.comBuy Rating on Petros Pharmaceuticals Amid Positive User Experience and Strategic FDA Pathway ComplianceDecember 12, 2023 | benzinga.comPetros Pharma Stock (NASDAQ:PTPI) Insider TradesDecember 12, 2023 | finance.yahoo.comPetros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor’s (rosuvastatin) OTC Switch Technology ProviderDecember 12, 2023 | finance.yahoo.comPetros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) (avanafil) the First Erectile Dysfunction Medication to Achieve OTC StatusDecember 9, 2023 | nasdaq.comMaxim Group Initiates Coverage of Petros Pharmaceuticals (PTPI) with Buy RecommendationDecember 9, 2023 | benzinga.comPetros Pharma Stock (NASDAQ:PTPI), Analyst Ratings, Price Targets, PredictionsDecember 8, 2023 | realmoney.thestreet.comPetros Pharmaceuticals initiated with bullish view at MaximDecember 7, 2023 | morningstar.comPetros Pharmaceuticals Inc Ordinary SharesDecember 5, 2023 | finanznachrichten.dePetros Pharmaceuticals, Inc.: Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor's OTC Switch Technology ProviderDecember 5, 2023 | finance.yahoo.comPetros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor's (rosuvastatin) OTC Switch Technology ProviderOctober 30, 2023 | finance.yahoo.comPetros Pharmaceuticals Petros Pharmaceuticals Developing Artificial Intelligence Technology for Phase 2 Equivalent Study for STENDRA(R)October 19, 2023 | finance.yahoo.comFollowing Encouraging FDA Feedback Petros Pharmaceuticals Initiates Self-Selection (Phase 2-Equivalent) Study for STENDRAOctober 4, 2023 | finanznachrichten.dePetros Pharmaceuticals, Inc.: Petros Pharmaceuticals Announces Positive Outcomes in Label Comprehension Study for Potential OTC STENDRA LabelOctober 4, 2023 | finance.yahoo.comPetros Pharmaceuticals Announces Positive Outcomes in Label Comprehension Study for Potential OTC STENDRA LabelSeptember 28, 2023 | finance.yahoo.comPetros Pharmaceuticals to Present at the LD Micro Main Event XVISeptember 11, 2023 | finanznachrichten.dePetros Pharmaceuticals, Inc.: Petros Pharmaceuticals Provides Letter to ShareholdersSeptember 11, 2023 | finance.yahoo.comPetros Pharmaceuticals Provides Letter to ShareholdersSeptember 6, 2023 | finanznachrichten.dePetros Pharmaceuticals, Inc.: Petros Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceSeptember 6, 2023 | finance.yahoo.comPetros Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceJuly 14, 2023 | marketwatch.comPetros Pharmaceuticals Down 9% After Capital Raise NewsJuly 13, 2023 | benzinga.comPetros Pharmaceuticals Announces $15M Private PlacementJuly 13, 2023 | finance.yahoo.comPetros Pharmaceuticals Announces Capital Raise of $15 MillionJuly 12, 2023 | marketbeat.comTrading was temporarily halted for "PTPI" at 11:07 AM with a stated reason of "LULD pause."July 12, 2023 | marketbeat.comTrading was temporarily halted for "PTPI" at 11:07 AM with a stated reason of "LULD pause."April 21, 2023 | marketbeat.comTrading was temporarily halted for "PTPI" at 09:04 AM with a stated reason of "LULD pause."April 20, 2023 | marketbeat.comTrading was temporarily halted for "PTPI" at 10:04 AM with a stated reason of "LULD pause."April 20, 2023 | marketbeat.comTrading was temporarily halted for "PTPI" at 09:04 AM with a stated reason of "LULD pause."April 18, 2023 | marketbeat.comTrading was temporarily halted for "PTPI" at 09:04 AM with a stated reason of "LULD pause."April 17, 2023 | marketbeat.comTrading was temporarily halted for "PTPI" at 10:04 AM with a stated reason of "LULD pause."April 17, 2023 | marketbeat.comTrading was temporarily halted for "PTPI" at 09:04 AM with a stated reason of "LULD pause."April 14, 2023 | msn.comUS Equity Futures Mixed Ahead of Retail Sales, Industrial Production, Consumer Sentiment ReportsApril 14, 2023 | investorplace.comWhy Is Petros Pharmaceuticals (PTPI) Stock Up 101% Today?March 6, 2023 | marketbeat.comTrading was temporarily halted for "PTPI" at 09:03 AM with a stated reason of "LULD pause."November 30, 2022 | finanznachrichten.dePetros Pharmaceuticals, Inc.: Petros Pharmaceuticals Announces Reverse Stock SplitNovember 30, 2022 | finance.yahoo.comPetros Pharmaceuticals Announces Reverse Stock Split Get Petros Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PTPI and its competitors with MarketBeat's FREE daily newsletter. Email Address The Only Energy Play You Should Be Looking At (Ad)Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy. Click here to get all the information about it. PTPI Media Mentions By Week PTPI Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PTPI News Sentiment▼1.560.77▲Average Medical News Sentiment PTPI News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PTPI Articles This Week▼30▲PTPI Articles Average Week Get Petros Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PTPI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: NexImmune News Today Tharimmune News Today Kazia Therapeutics News Today Alzamend Neuro News Today Artelo Biosciences News Today Clever Leaves News Today Genprex News Today China Pharma News Today NovaBay Pharmaceuticals News Today Exicure News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PTPI) was last updated on 6/3/2024 by MarketBeat.com Staff From Our PartnersTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBill Gates is all about this tiny $2 stockTimothy SykesBiden Nomination CANCELED?The Freeport SocietyExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsWrite this ticker symbol down…StocksToTradeShocking $16T Elon Musk Crypto LeakCrypto 101 MediaBiden replacement revealed?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Petros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
